Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.
about
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.High-Performance Liquid Chromatography (HPLC) Quantification of Liposome-Delivered Doxorubicin in Arthritic Joints of Collagen-Induced Arthritis Rats.Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis.Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.Heparosan-coated liposomes for drug delivery.Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.Drug governs the morphology of polyalkylated block copolymer aggregates.Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cellsWhat Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future
P2860
Q27300391-EC9923A2-F5B9-4266-8727-30D26F503620Q30366990-74A757C5-21AE-4BA2-830F-E88C168D9C8FQ33589526-E24DC051-6BA0-4636-A554-0F801B9B6E4DQ33891408-5E5D67E8-A623-4FD6-9AEE-F6443D626C66Q35374807-AD581732-3DAB-492C-8DD1-E652A8730F67Q36126057-2978C9CA-20B6-48A4-8CAA-3A169E36A7C3Q36583169-80AD26DA-1154-4C84-B486-90AEBC5580D7Q37602839-45039883-73B7-41B4-97C7-374C300A6DAFQ38233071-C5BA2BF4-9CA2-42A2-8ADD-AFC101106FD7Q38351134-FB25310D-DC12-46A8-A636-183EEAAAC5B5Q38792519-1861B281-C49C-49BB-B297-8CB728B9C1A3Q38973056-C1A102DD-5A17-4D7A-8088-0F6B6C0DDBD1Q39458957-46537EDD-2232-40AC-A5CA-C91FD5A29366Q40182586-FCD49AA2-D442-41FF-B6E0-6301D7593076Q41280444-510ECF78-A736-4861-95AF-5F5BA00D4322Q41929512-F905BD45-60EE-462B-AA8D-9995741DB032Q48627793-04E3D1BD-87A4-4F7D-9D39-E3EF8E1D7C5EQ51012619-4366E204-E4AC-4544-97A9-E9959DBCBB05Q51082836-02947DC5-2552-48FE-8644-4866CC4B68E1Q58747454-31C7E9A0-87D4-498F-B208-1670530E1079Q59128232-BF06DFF9-7B48-44F7-80AE-5100FA2F49CE
P2860
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@ast
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@en
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@nl
type
label
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@ast
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@en
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@nl
prefLabel
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@ast
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@en
Pharmacokinetics and efficacy ...... ranial model of breast cancer.
@nl
P2093
P2860
P50
P1433
P1476
Pharmacokinetics and efficacy ...... cranial model of breast cancer
@en
P2093
Allison M Deal
Allison Schorzman
Barbara Adamo
Carey K Anders
Charlene Santos
David Darr
Lisa Carey
Olga Karginova
Sumit Rawal
P2860
P304
P356
10.1371/JOURNAL.PONE.0061359
P407
P577
2013-05-01T00:00:00Z